Search results
Collagen
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome, storage pool disease) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDs and GPIIb/IIIa inhibitors.
Contact
Corn Trypsin Inhibitor (CTI)
FXIIa inhibitor.
DOAC-Remove™20
Removes DOACs and argatroban from citrated plasmas thereby reducing interference when the plasma is tested in laboratory coagulation assays such as aPTT, TT, single factors, lupus AC, and APC-R.
DOAC-Remove™250
Removes DOACs and argatroban from citrated plasmas thereby reducing interference when the plasma is tested in laboratory coagulation assays such as aPTT, TT, single factors, lupus AC, and APC-R.
DOAC-Remove™50
Removes DOACs and argatroban from citrated plasmas thereby reducing interference when the plasma is tested in laboratory coagulation assays such as aPTT, TT, single factors, lupus AC, and APC-R.
DOACs (Direct oral Anticoagulants)
DP-Filter®
DP-Filter®is effective in filtering direct oral anticoagulants (DOACs), which interfere in various coagulometric coagulation tests, from citrated plasma providing anticoagulant-free plasma that can be used for testing. For research use only.
Dabigatran (Pradaxa®) Control Plasma
Quality control titrated and optimized for anti-IIa colorimetric assays (HEMOCLOT Thrombin Inhibitors: ref. CK002K/CK002L).
Dabigatran (Pradaxa®) Control Plasma (low range)
Quality control titrated and optimized for anti-IIa colorimetric assays (HEMOCLOT Thrombin Inhibitors: ref. CK002K/CK002L).